Best and Worst Foods on GLP-1s, According to Dietitian Guidance

There is no official “GLP-1 diet.” The FDA labels for Wegovy and Zepbound say only that the drugs are used in combination with a reduced-calorie diet and increased physical activity, and the pivotal trials operationalized that as roughly a 500 kcal/day deficit plus at least 150 minutes of activity a week [1][2].

What exists instead is a growing body of clinical-nutrition guidance — mostly narrative reviews and dietitian recommendations, much of it borrowed from bariatric surgery practice, because that is the closest well-studied analogue. This page organizes what those sources say, and marks clearly where the evidence is thin.

None of this is medical advice. Food choices interact with medications, allergies, kidney function and existing conditions, and a registered dietitian or prescriber is the right person to individualize them.

About the label material on this page. Where this article describes dosing schedules, escalation, missed doses, storage or warnings, it is summarizing the FDA-approved prescribing information and Instructions for Use for Wegovy and Zepbound as published on DailyMed. Those documents are the authority, they are revised periodically, and they differ by product and by presentation (pen, prefilled syringe, single-dose vial, multi-dose vial). Follow the Instructions for Use that came with your own prescription, and take any question about your own dose, timing or supply to your prescriber or pharmacist rather than to this page.

What is the actual problem these foods are solving?

Two things happen on these drugs that change what food does.

Appetite is suppressed and meal capacity shrinks. In a 20-week randomized trial of 72 adults that measured intake at a self-served lunch, participants on semaglutide 2.4 mg ate 35% fewer calories than placebo [3]. Fewer calories means fewer opportunities for nutrition.

Gastric emptying slows. This is part of how the drugs work, and it is also why a meal that used to sit comfortably may now sit for hours.

Everything in the “best foods” list follows from the first problem — nutrient density per bite. Everything in the “worst foods” list follows from the second — anything that slows digestion further, or arrives in too large a volume.

What do dietitians recommend eating?

Protein first, spread across the day. Mayo Clinic registered dietitian Tara Schmidt frames it simply: when your appetite shrinks, every bite has to count, so prioritize nutrient-dense foods that provide high-quality protein, fiber, and essential vitamins and minerals [4].

Complete proteins — those with adequate amounts of all nine essential amino acids — include dairy, meat, eggs, fish, poultry and soy foods. Many plant foods provide protein but may be lower in one or more essential amino acids [4]. Useful reference points from Mayo’s list:

Food	Protein
Cottage cheese, reduced fat, 1 cup	26 g
Greek yogurt, plain, whole milk, 1 cup	22 g
Canned tuna	23 g
Tempeh, 1 cup	34 g
Soybeans, boiled, 1 cup	31 g
Black beans, 1 cup	15 g
Chickpeas, 1 cup	14-15 g
Firm tofu	10 g
Milk, reduced fat, 1 cup	8 g
Cheddar cheese, 1 oz	7 g

The target most healthy adults are pointed toward is about 20-30 g of protein per meal, spread through the day rather than concentrated at dinner, though individual needs differ by age, activity and health conditions [4].

Foods that go down easily when appetite is low. The 2025 American Journal of Clinical Nutrition review on nutritional priorities is specific here: small, frequent meals may work well when hunger and interest in food are low, and “healthfully prepared smoothies and protein drinks with fruits, vegetables, and various unsweetened milks or yogurt; cottage cheese and soups can provide needed nutrients and are often more appealing to individuals than heavier foods such as red meats, cold cuts, or hard cheeses” [5].

That line is worth reading twice, because it inverts what a lot of people assume. Heavy protein sources are often the hardest to get down, not the easiest.

Fiber, introduced gradually. Constipation is one of the most common problems on these drugs. In the two 72-week trials behind the 7.2 mg label section, constipation was reported by 19% of people on semaglutide 2.4 mg and 20% on 7.2 mg, against 8% on placebo; in the pooled 2.4 mg weight-management trials the label reports 24% versus 11% on placebo [1]. Bariatric-derived guidance points to increasing fiber and fluid intake together [6]. A 2026 review of viscous fibers notes that appetite suppression, reduced meal volume, delayed transit and constipation all tend to cut fiber intake at exactly the moment bowel function needs support, and that psyllium has the strongest clinical evidence for stool normalization, glycemic modulation and LDL reduction [7]. Glucomannan provides more viscosity but requires adequate hydration and is less well tolerated. Supplement decisions belong with a prescriber, given the delayed gastric emptying.

Carbohydrates, reallocated rather than cut. A small cross-sectional study of 69 GLP-1 users, using three-day food records, found participants consuming more calories from fat than from carbohydrate, with saturated fat averaging about 6 g/day above recommended limits. The authors’ recommendation was not to cut carbs but to shift dietary fat intake and reallocate calories to fiber-rich carbohydrates and protein [8]. Sixty-nine people is a signal, not a population estimate.

Fluids, separated from meals. Bariatric protocols routinely separate fluid from solid intake so liquid does not take up limited stomach capacity, and the bariatric-derived GLP-1 framework carries this across [6].

What causes trouble?

Fat is the most consistently named problem. Dietary fat naturally slows digestion. Combining a higher-fat diet with a drug that already delays gastric emptying may further increase gastrointestinal discomfort [8]. This is the single most repeated mechanism in the literature.

Shannon Christen, a dietitian and diabetes educator at UCHealth University of Colorado Hospital quoted in Associated Press reporting on GLP-1 food labeling, advises GLP-1 users to choose foods with less than 10 grams of fat per serving because fat can worsen symptoms like nausea and acid reflux [9]. That is practical clinical advice from one clinician, not a validated threshold and not something any trial has tested — but it is the most concrete number anyone has put on it.

Large portions. Meal size and dietary composition influence gastrointestinal tolerability directly [10]. Small and frequent beats large and infrequent on these drugs, which is the opposite of how many people were previously advised to eat.

Heavy, dense foods when appetite is low. Red meats, cold cuts and hard cheeses are specifically named in the AJCN review as foods people often find less appealing than lighter alternatives [5].

Fried foods, by combining high fat with large volume.

Alcohol. Not a nausea trigger for everyone, but a separate consideration — see the section below.

Carbonated drinks are commonly avoided in bariatric practice for comfort reasons, though the GLP-1-specific evidence for this is not established.

What the research actually says about taste and aversions

This is where consumer articles get sloppiest, so it is worth being precise.

Formal taste testing found measurable change. A case-control study compared 46 people taking GLP-1 receptor agonists with 46 matched controls using the 53-item Waterless Empirical Taste Test and the 40-item University of Pennsylvania Smell Identification Test. Taste scores were significantly lower in the GLP-1 group (mean 28.61 vs 40.63), with all five basic taste qualities affected. Eighty-five percent of GLP-1 participants scored worse than their individually matched control. Smell was only slightly and non-significantly reduced. Oddly, taste and smell scores were better in those reporting nausea and diarrhea [11].

Self-report tells a different story. A cross-sectional survey of 411 adults on Wegovy, Ozempic or Mounjaro found 58.4% reported reduced appetite and 63.5% increased satiety — but on taste, the majority reported no change. About 20-30% reported increased intensity in sweet, salty, bitter or sour. Increased sweet-taste perception was associated with increased satiety (adjusted odds ratio 2.02), decreased appetite (1.67) and decreased craving (1.87), though it was not associated with actual BMI reduction [12].

A 2026 review argues the confusion is definitional. Writing in Frontiers in Nutrition, the authors propose separating what people report into three levels [13]:

• Sensory — the food genuinely tastes different.
• Liking — the food is less enjoyable while you are eating it.
• Wanting — the food is less tempting, even when it is in front of you.

Their conclusion: current evidence does not support a consistent primary impairment of basic taste function during GLP-1 therapy. Reports are more consistent with state-dependent food revaluation and reduced reward-driven motivation. They also note that taste complaints frequently co-occur with nausea, early satiety, reflux and dry mouth, which makes separating true sensory change from everything else genuinely hard at the bedside [13].

The practical upshot is unchanged either way: if particular foods have become unappealing, the goal is finding acceptable substitutes that hit the same nutritional targets — not forcing the original food down. The bariatric-derived framework treats altered food preferences as a distinct clinical problem requiring behavioral nutrition therapy, patient education on food choices, and psychological support where needed [6].

Alcohol on a GLP-1

Two things are true and they point in different directions.

First, there is now randomized evidence that semaglutide reduces drinking. A 26-week single-center trial (SEMALCO) in treatment-seeking adults with moderate-to-severe alcohol use disorder and comorbid obesity — all of whom also received standard cognitive behavioral therapy — found heavy drinking days fell 41.1 percentage points with semaglutide 2.4 mg versus 26.4 with placebo, a treatment difference of -13.7 percentage points (p=0.0015), with improvements across total consumption, drinks per drinking day and craving measures [14]. An earlier phase 2 trial in 48 adults found low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day and weekly craving [15]. A 2026 trial of oral semaglutide reported fewer heavy drinking days and lower cravings [16].

Second, no GLP-1 is approved for alcohol use disorder, and none of these trials tested alcohol as a lifestyle question for people taking the drug for weight. What the label does say is relevant though: the most common adverse reactions are gastrointestinal, and there is a warning for acute kidney injury due to volume depletion, with most reported events occurring in patients whose nausea, vomiting or diarrhea led to dehydration [1]. Alcohol does not help with either.

Many people report simply wanting to drink less. That is consistent with the trial data. If you drink and are starting one of these drugs, it is a reasonable thing to raise with a prescriber.

Are “GLP-1 friendly” packaged foods worth it?

A whole retail category has appeared. Nestlé launched Vital Pursuit in 2024 as a 12-SKU frozen line marketed as a companion for GLP-1 users at $4.99 or less, adding a “GLP-1 Friendly” label later at customer request [17]. Conagra put an “On Track / GLP-1 Friendly” badge on 26 existing Healthy Choice meals from January 2025, without changing the recipes, starting with Café Steamers ($3.49) and Simply Steamers ($3.99) [18]. Smoothie King has a GLP-1 Support Menu built with Ochsner Health dietitians, with items listing 19-24 g protein and 5-15 g fiber [19] — though the Associated Press noted that its 20-ounce Gladiator GLP-1 Vanilla smoothie carries more calories, sodium and cholesterol than an original glazed Krispy Kreme donut [9]. Factor sells a “GLP-1 Balance” plan and Daily Harvest a GLP-1 collection. None of these products has been tested in a clinical trial.

The honest verdict, from the people who study labeling:

• USDA’s Food Safety and Inspection Service approved the “GLP-1 Friendly” labels because they are accompanied by statements about protein and fiber content and are not misleading — while stating explicitly that there is no regulatory standard for the term [9].
• A food-policy expert quoted by NPR put it bluntly: “There is absolutely no regulated or medically defined standard, so the labels are just marketing” [20].
• Nutrition content varies. Vital Pursuit’s Cauliflower Crust Three Meat Pizza has 400 calories and 32% of the daily value for protein — but also 40% of the recommended sodium and saturated fat, and 18 g of fat [9].

Convenience is a real benefit, particularly for people who live alone or do not want to cook when appetite is low [9]. It is also worth knowing who is actually buying: Nestlé told the AP that 77% of Vital Pursuit sales come from households where nobody is using a GLP-1 drug [9]. The right way to use these products is to ignore the badge and read the panel: protein per serving, fat per serving, sodium, fiber, and total calories. The badge tells you nothing the panel does not.

Is what people buy actually changing?

Yes, measurably. A study published in the Journal of Marketing Research in December 2025 linked survey data on GLP-1 use with Numerator transaction records from about 150,000 US households. Within six months of starting, households cut grocery spending by an average of 5.3%, and by more than 8% among higher-income households. Spending at limited-service restaurants — fast food and coffee shops — fell about 8%. The sharpest declines were in ultra-processed, calorie-dense foods, with savory snacks dropping notably. Lower spending persisted at least a year among continuing users and faded after discontinuation [21].

That is a population-level pattern, not a prescription. But it does suggest the food changes people describe are real and consistent enough to show up in national purchase data.

What the guidance adds up to

Not a meal plan and not a prescription — a summary of what the clinical-nutrition literature cited on this page recommends. Individual plans belong to a registered dietitian or prescriber, who can account for allergies, kidney function, diabetes medication and everything else on your chart.

• Protein at every eating occasion, roughly 20-30 g in Mayo’s consumer framing [4].
• Nutrient density over volume, because there are fewer bites to work with [4][5].
• Lower fat, particularly when nausea or reflux is present, since fat compounds delayed gastric emptying [8].
• Smaller, more frequent meals rather than three large ones [5][10].
• Eating slowly, and separating fluids from meals, both carried over from bariatric nutrition practice [6].
• Fiber and fluid increased together and gradually [6][7].
• Liquids — smoothies, soups, yogurt drinks — when solids will not go down [5].
• Read the nutrition panel, not the badge. The badge has no regulatory meaning [9].
• Raise a persistent inability to eat with a prescriber rather than pushing through; the labels warn that dehydration from gastrointestinal reactions has led to acute kidney injury [1][2].

Sources

1. Wegovy (semaglutide) prescribing information via DailyMed, June 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Zepbound (tirzepatide) prescribing information via DailyMed, revised August 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism 2021;23(3):754-762. https://doi.org/10.1111/dom.14280
4. Noble D. Eating well on GLP-1 medications. Mayo Clinic Press, September 2026. https://mcpress.mayoclinic.org/healthy-eating/eating-well-on-glp-1-medications-smaller-appetites-need-quality-nutrition/
5. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr 2025. https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
6. Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 RA therapy assisted weight loss. Int J Obes 2025. https://doi.org/10.1038/s41366-025-01952-w
7. Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis. Int J Mol Sci 2026. https://doi.org/10.3390/ijms27146287
8. Johnson B et al. Investigating nutrient intake during use of GLP-1 receptor agonist. Frontiers in Nutrition 2025. https://doi.org/10.3389/fnut.2025.1566498
9. GLP-1 Friendly food labels becoming more common in supermarkets (AP via Las Vegas Review-Journal), January 2026. https://www.reviewjournal.com/livewell/food-labels-target-users-of-weight-loss-drugs-3611064/
10. Adherence and Persistence with GLP-1-Based Therapies. Nutrients 2026. https://doi.org/10.3390/nu18111761
11. Khan R, Doty RL. GLP-1 receptor agonists significantly impair taste function. Physiology & Behavior 2025. https://www.sciencedirect.com/science/article/abs/pii/S003193842400341X
12. Kapan A et al. Real-world insights into incretin-based therapy: associations between changes in taste perception and appetite regulation. Diabetes Obes Metab 2025. https://doi.org/10.1111/dom.16548
13. Du Y et al. Altered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference. Frontiers in Nutrition, July 2026. https://doi.org/10.3389/fnut.2026.1870484
14. Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. The Lancet 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext
15. Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry 2025. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
16. Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz, July 2026. https://news.cuanschutz.edu/news-stories/can-oral-semaglutide-reduce-alcohol-use-cu-anschutz-clinical-trial-shows-fewer-heavy-drinking-days
17. Nestlé Introduces Vital Pursuit Brand. Nestlé USA. https://www.nestleusa.com/media/pressreleases/vital-pursuit-glp-1-weight-manage
18. Conagra Brands Introduces Badges on Select Healthy Choice Products, December 2024. https://www.conagrabrands.com/news-room/news-conagra-brands-introduces-badges-on-select-healthy-choice-products-leading-consumers-to-glp-1-friendly-options-prn-122909
19. Smoothie King GLP-1 Smoothies. https://www.smoothieking.com/landing-pages/glp-1-smoothies/
20. Noguchi Y. What do the new ‘GLP-1 Friendly’ food labels mean? NPR, March 2026. https://www.npr.org/2026/03/23/nx-s1-5699407/glp-1-ozempic-zepbound-wegovy-nutrition
21. Ozempic is changing the foods Americans buy. Cornell Chronicle, December 2025. https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buy